BioPharma Dive’s report, leveraging DealForma’s data, uncovers a steep decline in investment for cell and gene therapy developers, attributed to manufacturing and drug delivery challenges, as investors increasingly favor biotechnology companies with more defined development paths. Check out Biopharma Dive’s report.
